WO2004043396A3 - Modified carbamate-containing prodrugs and methods of synthesizing same - Google Patents

Modified carbamate-containing prodrugs and methods of synthesizing same Download PDF

Info

Publication number
WO2004043396A3
WO2004043396A3 PCT/US2003/035995 US0335995W WO2004043396A3 WO 2004043396 A3 WO2004043396 A3 WO 2004043396A3 US 0335995 W US0335995 W US 0335995W WO 2004043396 A3 WO2004043396 A3 WO 2004043396A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
prodrugs
active agent
biologically active
carbamate
Prior art date
Application number
PCT/US2003/035995
Other languages
French (fr)
Other versions
WO2004043396A2 (en
Inventor
Nnochiri N Ekwuribe
Jennifer Riggs-Sauthier
Tatyana Dyakonov
Original Assignee
Nobex Corp
Nnochiri N Ekwuribe
Jennifer Riggs-Sauthier
Tatyana Dyakonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corp, Nnochiri N Ekwuribe, Jennifer Riggs-Sauthier, Tatyana Dyakonov filed Critical Nobex Corp
Priority to AU2003285200A priority Critical patent/AU2003285200A1/en
Publication of WO2004043396A2 publication Critical patent/WO2004043396A2/en
Publication of WO2004043396A3 publication Critical patent/WO2004043396A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Abstract

Prodrugs having a hydrolyzable carbamate moiety, compositions including the prodrugs, methods of preparing the prodrugs and methods of treatment using the prodrugs are disclosed. The prodrug has the formula DC(X)XR, where D is a biologically active agent, X is O, S or NR , and R is a moiety that modifies various properties of the biologically active agent. The biologically active agent either includes a functional group such as an amide, thioamide, imide, thioimide, urea, thiourea, carbamate, thiocarbamate, sulfonamide, or sulfonimide group, or includes a hydroxy, amine, carboxylic acid or thiol group that is modified to include such a group. An NH group from the biologically active agent can be coupled to an activated form the C(X)XR moiety to form the prodrugs described herein. Relative to a conventional carbamate group, the presence of the additional carbonyl or sulfonyl group makes the carbamate group more susceptible to hydrolysis. The prodrugs are more stable in certain environments than the biologically active agent, and can permit the drugs to be administered orally, in those embodiments where the biologically active agent must otherwise be administered by injection or intraveneous administration.
PCT/US2003/035995 2002-11-09 2003-11-07 Modified carbamate-containing prodrugs and methods of synthesizing same WO2004043396A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003285200A AU2003285200A1 (en) 2002-11-09 2003-11-07 Modified carbamate-containing prodrugs and methods of synthesizing same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42479602P 2002-11-09 2002-11-09
US60/424,796 2002-11-09
US48367603P 2003-06-30 2003-06-30
US60/483,676 2003-06-30

Publications (2)

Publication Number Publication Date
WO2004043396A2 WO2004043396A2 (en) 2004-05-27
WO2004043396A3 true WO2004043396A3 (en) 2004-08-12

Family

ID=32314558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035995 WO2004043396A2 (en) 2002-11-09 2003-11-07 Modified carbamate-containing prodrugs and methods of synthesizing same

Country Status (4)

Country Link
US (1) US20040152769A1 (en)
AU (1) AU2003285200A1 (en)
TW (1) TW200418451A (en)
WO (1) WO2004043396A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422363B2 (en) 2007-08-28 2016-08-23 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
KR101168620B1 (en) 2003-12-16 2012-08-03 넥타르 테라퓨틱스 Pegylated small molecules
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AU2007343796A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
WO2008153745A2 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
KR20100061486A (en) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 Use of a peptide as a therapeutic agent
US20100204145A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009040073A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009033765A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP2010538994A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of BFGF1-24 and optionally (ARG8) vasopressin, for example to treat Streptococcus pneumoniae infection
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2344201A1 (en) * 2008-09-17 2011-07-20 Nektar Therapeutics Oligomer-protease inhibitor conjugates
CA2758581C (en) 2009-05-20 2022-06-14 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US20120108501A1 (en) * 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
JP5848761B2 (en) 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Prodrugs of NH acidic compounds: derivatives of esters, carbonates, carbamates and phosphonates
EP2624869A4 (en) * 2010-10-08 2015-11-04 Univ Virginia Commonwealth Prodrugs utilizing a transporter directed uptake mechanism
US9540330B2 (en) 2010-12-15 2017-01-10 Nektar Therapeutics Oligomer-containing hydantoin compounds
EP3094643B1 (en) * 2014-01-15 2018-10-17 Fyziologicky ustav Akademie ved Ceske republiky, v.v.i. Lipidated peptides for lowering blood glucose
CN104945499B (en) * 2014-03-31 2019-12-10 博瑞生物医药（苏州）股份有限公司 GLP-1 analogue with modified structure and preparation method thereof
US9399044B2 (en) 2014-05-28 2016-07-26 International Business Machines Corporation Antimicrobial cationic polyamines
JP7081923B2 (en) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション Higher effectiveness for removing apoE mimetic peptides and plasma cholesterol
WO2019058365A1 (en) 2017-09-19 2019-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Somatostatin prodrugs
CN111163807A (en) * 2017-09-19 2020-05-15 耶路撒冷希伯来大学伊森姆研究发展有限公司 Lipophilic peptide prodrugs

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006581A1 (en) * 1986-04-30 1987-11-05 Farmaceutisk Laboratorium Ferring A/S A prodrug form of 5-fluorouracil and a method of treatment of cancer
WO1988001615A1 (en) * 1986-08-26 1988-03-10 Hans Bundgaard Prodrug derivatives of carboxylic acid drugs
EP0148883B1 (en) * 1983-06-30 1990-02-14 A/S GEA Farmaceutisk Fabrik Allopurinol prodrugs
WO1990008128A1 (en) * 1989-01-20 1990-07-26 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
WO1991003487A1 (en) * 1989-09-04 1991-03-21 Hans Bundgaard Prodrug derivatives of thyrotropin-releasing hormone (trh)
WO1992022530A1 (en) * 1991-06-13 1992-12-23 H. Lundbeck A/S Ketobemidone prodrugs
WO1993001197A1 (en) * 1991-07-03 1993-01-21 Perstorp Ab Derivatives of inositol, preparations containing them and their use
EP0557385B1 (en) * 1990-11-16 1998-07-22 Pharmacia & Upjohn Aktiebolag Topical compositions for transdermal delivery of produg derivatives of morphine

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) * 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0092918B1 (en) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4760057A (en) * 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
US5108568A (en) * 1989-07-07 1992-04-28 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5220059A (en) * 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
FR2676058B1 (en) * 1991-04-30 1994-02-25 Hoechst Lab GLYCOSYLATED PRODUCTS, THEIR PREPARATION PROCESS AND THEIR USE IN THE TREATMENT OF CANCERS.
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5413992A (en) * 1992-07-31 1995-05-09 The Scripps Research Institute Daunomycin derivative with reduced cytotoxicity toward normal cells
DE4236237A1 (en) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, their preparation and use as medicines
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5668151A (en) * 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
CA2245835A1 (en) * 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US6638508B2 (en) * 1995-12-21 2003-10-28 Yeda Research And Development Co., Ltd. Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
PT914344E (en) * 1996-03-04 2005-10-31 Scios Inc TEST AND REAGENTS FOR HBNP QUANTIFICATION
US6590088B1 (en) * 1996-07-19 2003-07-08 Human Genome Sciences, Inc. CD33-like protein
IL134084A0 (en) * 1997-07-18 2001-04-30 Infimed Inc Biodegradable macromers for the controlled release of biologically active substances
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6225444B1 (en) * 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
EP1056773A2 (en) * 1998-02-11 2000-12-06 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (en) * 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
JP2003507438A (en) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド Enhanced delivery of drugs across and into epithelial tissue using oligoarginine moieties
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
NO20004795D0 (en) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
US20030149235A1 (en) * 2000-11-17 2003-08-07 Baker Andrew Howard Targeting peptides
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
CA2463902A1 (en) * 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0148883B1 (en) * 1983-06-30 1990-02-14 A/S GEA Farmaceutisk Fabrik Allopurinol prodrugs
WO1987006581A1 (en) * 1986-04-30 1987-11-05 Farmaceutisk Laboratorium Ferring A/S A prodrug form of 5-fluorouracil and a method of treatment of cancer
WO1988001615A1 (en) * 1986-08-26 1988-03-10 Hans Bundgaard Prodrug derivatives of carboxylic acid drugs
WO1990008128A1 (en) * 1989-01-20 1990-07-26 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
WO1991003487A1 (en) * 1989-09-04 1991-03-21 Hans Bundgaard Prodrug derivatives of thyrotropin-releasing hormone (trh)
US5405834A (en) * 1989-09-04 1995-04-11 Bundgaard; Hans Prodrug derivatives of thyrotropin-releasing hormone (TRH)
EP0557385B1 (en) * 1990-11-16 1998-07-22 Pharmacia & Upjohn Aktiebolag Topical compositions for transdermal delivery of produg derivatives of morphine
WO1992022530A1 (en) * 1991-06-13 1992-12-23 H. Lundbeck A/S Ketobemidone prodrugs
WO1993001197A1 (en) * 1991-07-03 1993-01-21 Perstorp Ab Derivatives of inositol, preparations containing them and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUNDGAARD H: "DESIGN OF PRODRUGS", 1985, ELSEVIER *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422363B2 (en) 2007-08-28 2016-08-23 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use

Also Published As

Publication number Publication date
AU2003285200A1 (en) 2004-06-03
TW200418451A (en) 2004-10-01
AU2003285200A8 (en) 2004-06-03
US20040152769A1 (en) 2004-08-05
WO2004043396A2 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
WO2004043396A3 (en) Modified carbamate-containing prodrugs and methods of synthesizing same
DE69133466T2 (en) Retrovirus protease inhibitors
WO2002083111A3 (en) Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
AU623733B2 (en) Benzofused-n-containing heterocyle derivatives
CA2472954A1 (en) Aza-arylpiperazines
WO2005056524A3 (en) Therapeutic agents useful for treating pain
EP1396493A4 (en) Heterocyclic compounds
WO2002089782A3 (en) Dioxanes and uses thereof
AP2001002358A0 (en) Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4- pyrrolidin-1-yl-butyl)ureido]-isothiazole-4-carboxilic acid amide and method of production.
EP1813270A4 (en) Hsp90 family protein inhibitors
WO2003094854A3 (en) Succinoyl aminopyrazoles and related compounds
KR900003163A (en) Cyclohexane derivatives
US20220168279A1 (en) Methods of treating pain with a thiazoline anti-hyperalgesic
EP1671957A4 (en) Thiadiazoline derivatives
EP1167369A4 (en) Novel thiazolobenzimidazole derivatives
ATE126796T1 (en) QUINAZOLINE DERIVATIVES AND THEIR PRODUCTION.
WO2003053337A3 (en) Therapeutic compositions
WO2003018010A1 (en) Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
EP1149832A4 (en) Benzamide derivatives and drugs containing the same
CA2382654A1 (en) Novel a-500359 derivatives
WO2008136377A1 (en) Bicyclic heterocyclic compound
EP1174421A4 (en) 3-amidinobenzenesulfonamide derivatives, medicinal compositions containing the same and intermediates in the production thereof
MXPA04000485A (en) Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors.
EP2088152A4 (en) N'-{n-[3-oxo-lupen-28-oyl]-9-aminononanoyl}-3-amino-3-phenylpropeonic acid and the pharmaceutically acceptable derivatives thereof, a method for the production and the use thereof in the form of a medicinal agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP